tiprankstipranks
Trending News
More News >
Statera BioPharma (STAB)
OTHER OTC:STAB
US Market
Advertisement

Statera BioPharma (STAB) Price & Analysis

Compare
190 Followers

STAB Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

<0.01%100.00%
Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors

STAB FAQ

What was Statera BioPharma’s price range in the past 12 months?
Currently, no data Available
What is Statera BioPharma’s market cap?
Statera BioPharma’s market cap is $7.14K.
    When is Statera BioPharma’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Statera BioPharma’s earnings last quarter?
    Currently, no data Available
    Is Statera BioPharma overvalued?
    According to Wall Street analysts Statera BioPharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does Statera BioPharma pay dividends?
      Statera BioPharma does not currently pay dividends.
      What is Statera BioPharma’s EPS estimate?
      Statera BioPharma’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does Statera BioPharma have?
      Statera BioPharma has 71,416,040 shares outstanding.
        What happened to Statera BioPharma’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of Statera BioPharma?
        Currently, no hedge funds are holding shares in STAB

        Company Description

        Statera BioPharma

        Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.
        Similar Stocks
        Company
        Price & Change
        Follow
        Biodexa Pharmaceuticals
        Salarius Pharmaceuticals
        Processa Pharmaceuticals
        GRI Bio
        Onconetix
        Popular Stocks
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis